As Peptides Go Mainstream, USP <795> and <797> Matter More Than Ever

Over the past year, peptides have moved from a niche offering in pharmacy and wellness into the center of a rapidly expanding market. Clinics are offering peptide protocols as part of routine care. Telehealth platforms are scaling peptide access nationwide. Compounding pharmacies are fielding increased demand for custom formulations. Investors and operators have taken notice.

With that growth has come attention, not just from consumers but from regulators, boards of pharmacy, and, increasingly, plaintiffs’ attorneys. In many ways, the peptide market in 2024 and 2025 resembled other fast-growing, lightly regulated health care sectors in their early stages. Innovation outpaced oversight. Business models evolved faster than compliance infrastructure. Many operators assumed that if they were generally careful and avoided obvious mistakes, scrutiny would remain limited.

That assumption is no longer reliable.

As an attorney representing pharmacies and operators in highly regulated industries, I have seen how quickly peptide operations can move from routine business to regulatory focus. When that happens, United States Pharmacopeia (USP) chapters <795> Pharmaceutical Compounding—Nonsterile Preparations and <797> Pharmaceutical Compounding—Sterile Preparations are often the first standards pulled off the shelf. What was once treated as guidance is now increasingly viewed as the baseline against which conduct is judged.

For peptide businesses that compound, prepare, or otherwise handle products intended for human use, the conversation has shifted. Compliance is no longer just about keeping inspectors satisfied. It is about protecting the business itself as the market matures and expectations harden. Understanding where USP <795> and <797> apply and how they are used in real-world enforcement has become essential.

Why USP <795> and <797> Matter More to Peptide Businesses Today

USP <795> governs nonsterile compounding, whereas USP <797> governs sterile compounding.^1,2 Although the USP is a standards-setting body rather than an enforcement agency, many state boards of pharmacy incorporate USP chapters directly into regulation.³ Even where they do not, inspectors, regulators, and even courts routinely look to the USP as evidence of the professional standard of care.^4,5

That distinction matters. Peptides increasingly sit at the intersection of clinical care and wellness. When peptides are compounded, reconstituted, modified, or prepared in a pharmacy or pharmacy-adjacent environment, USP standards often apply regardless of how the business markets itself. Labels and disclaimers rarely control outcomes. Process does.

USP <795>: Nonsterile Does Not Mean Low Risk

USP <795> applies to nonsterile compounded preparations, including certain peptide formulations, depending on how they are prepared and administered. Nonsterile compounding is sometimes treated as a lower-risk category, but that perception can be misleading. The key elements of <795> include risk categorization of compounded preparations; ingredient sourcing and verification; beyond-use dating (BUD) supported by stability data; documentation and recordkeeping; personnel training and hygiene; and cleaning and maintenance of compounding areas.¹

In my practice, one of the most common compliance gaps I see involves unsupported BUDs. Assigning BUDs based on habit, prior practice, or informal vendor guidance rather than documented stability information is an easy place for compliance to drift. It is also an easy place for regulators and plaintiffs’ attorneys to focus once questions arise.

Another recurring issue is documentation that appears sufficient on paper but does not reflect actual day-to-day practice. When inspectors ask not just what the standard of practice says but also how it is followed in real time, inconsistencies become apparent quickly and can spark future issues.

USP <797>: Where Compliance Expectations Sharpen

USP <797> governs sterile compounding and carries heightened expectations due to the risks associated with sterility failures.⁶ The revised chapter, which became official on November 1, 2023, modernized standards related to environmental controls and room classification, personnel training and competency assessment, and garbing and hygiene procedures, as well as cleaning, disinfection, and environmental monitoring.²

For peptide businesses involved in sterile preparation, this is often where scrutiny intensifies. Sterility failures are not abstract. They can result in contamination, infection, and serious patient harm.

I have seen situations in which USP <797> compliance, or the lack of it, became central not only to regulatory inquiries but also to civil litigation. In those cases, adherence to USP standards was treated as evidence of reasonable care, whereas deviations became focal points for liability.

Applicability: When USP Standards Apply

A frequent point of confusion in the peptide space is when USP standards apply. The answer is typically less about labels and more about how peptides are prepared and intended to be used.

When peptides are compounded, reconstituted, or prepared for human administration within a pharmacy setting, USP <795> and <797> often form the framework regulators use to assess compliance. Disclaimers such as “research use only” do not override observed practice when facts suggest otherwise. This is an area where businesses sometimes underestimate risk. Regulators and courts tend to look to substance over form.

Common Compliance Challenges in Peptide Operations

Across peptide businesses, several operational challenges appear repeatedly, including facilities that expanded rapidly without being designed around USP requirements, training programs that worked at a small scale but failed to keep pace with growth, blurred lines between sterile and nonsterile workflows, documentation that lagged behind operational change, and an overreliance on vendors or partners without adequate oversight. None of these issues is unusual. Left unaddressed, however, they compound.

Why This Matters Beyond Regulators

Even in jurisdictions where enforcement activity feels limited, civil exposure remains real. In litigation involving compounded products, USP <795> and <797> are frequently cited as evidence of the applicable standard of care. Plaintiffs’ attorneys often need not prove intentional misconduct. In certain instances, they need only to show deviation from accepted standards. When documentation is thin, training is inconsistent, or facilities fall short, those gaps quickly become leverage.

In other regulated industries, periods of rapid growth are often followed by tighter margins and closer oversight. Health care is no different. Operations that embed compliance early on are better positioned to withstand that shift.

Practical Steps for Alignment

Peptide businesses can take deliberate, structured steps to bring their operations into alignment with current USP expectations. The process often begins with a formal gap assessment against USP <795> and <797> to identify where policies, facilities, and workflows diverge from current standards. An honest review at this stage provides a practical road map rather than a defensive reaction.

From there, organizations should ensure that written standards of practice accurately reflect day-to-day workflow. Policies that exist only on paper create exposure and confusion. Procedures should be reviewed in light of actual practice, with adjustments made either to operations or to documentation so the two are aligned.

Personnel competency is another foundational element. Training should not only take place but also be verified and documented in a way that demonstrates ongoing proficiency. Competency assessments and refresher training reinforce both regulatory confidence and operational discipline.

Facility design and workflow separation also warrant close evaluation, particularly where sterile and nonsterile activities intersect. Physical layout, traffic patterns, environmental controls, and equipment placement should support the level of compounding being performed rather than undermine it.

Finally, routine internal audits can help maintain consistency over time. Regular review mechanisms allow organizations to identify small issues before they become larger compliance concerns and promote a culture of continuous improvement.

Effective compliance programs are proactive and sustained. They are embedded into daily operations and professional culture, not assembled in response to an inspection.

Looking Ahead

As peptide utilization grows, regulatory expectations will continue to evolve. USP <795> and <797> provide a shared framework for regulators, pharmacists, and courts when evaluating compounding practices. For peptide businesses, understanding and implementing these standards supports patient safety and long-term stability.⁷ More importantly, it reinforces the professional foundation of pharmacy practice in a rapidly changing market.

REFERENCES

1. United States Pharmacopeia. USP General Chapter <795>: Pharmaceutical Compounding - Nonsterile Preparations. USP-NF.

2. United States Pharmacopeia. General Chapter <797>: Pharmaceutical Compounding – Sterile Preparations. USP-NF.

3. United States Pharmacopeia. General Notices and Requirements. USP-NF.

4. Survey of Pharmacy Law. National Association of Boards of Pharmacy; 2026.

5. Federal Food, Drug, and Cosmetic Act, 21 USC §351(a)(2)(B) (2024). Accessed March 9, 2026. https://uscode.house.gov/view.xhtml?req=(title:21%20section:351%20edition:prelim)

6. Insanitary Conditions at Compounding Facilities: Guidance for Industry. FDA; 2020.

7. Institute for Safe Medication Practices (ISMP). Sterile Compounding Safety Alerts and Recommendations.